.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Teva
Cipla
US Army
QuintilesIMS
Chinese Patent Office
Cantor Fitzgerald
US Department of Justice
Deloitte

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204958

« Back to Dashboard
NDA 204958 describes KENGREAL, which is a drug marketed by Chiesi Usa Inc and is included in one NDA. It is available from two suppliers. There are eight patents protecting this drug. Additional details are available on the KENGREAL profile page.

The generic ingredient in KENGREAL is cangrelor. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the cangrelor profile page.

Summary for 204958

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:8
Formulation / Manufacturing:see details

Pharmacology for NDA: 204958

Mechanism of ActionP2Y12 Receptor Antagonists
Physiological EffectDecreased Platelet Aggregation

Suppliers and Packaging for NDA: 204958

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KENGREAL
cangrelor
POWDER;IV (INFUSION) 204958 NDA Chiesi USA, Inc. 10122-620 10122-620-10 10 VIAL, SINGLE-USE in 1 CARTON (10122-620-10) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE (10122-620-01)
KENGREAL
cangrelor
POWDER;IV (INFUSION) 204958 NDA The Medicines Company 65293-003 65293-003-10 10 VIAL, SINGLE-USE in 1 CARTON (65293-003-10) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE (65293-003-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;IV (INFUSION)Strength50MG/VIAL
Approval Date:Jun 22, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Jun 22, 2020
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:► SubscribePatent Expiration:Dec 11, 2017Product Flag?YSubstance Flag?Delist Request?
Patented Use:P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTIONTO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR
Patent:► SubscribePatent Expiration:Jun 29, 2018Product Flag?YSubstance Flag?Delist Request?
Patented Use:P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTIONTO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Accenture
McKinsey
Chubb
UBS
Cipla
QuintilesIMS
Federal Trade Commission
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot